In the Media

President-elect Joe Biden has selected Prof. Gary Gensler to serve as the next chair of the Securities and Exchange Commission, reports Marcy Gordon and Zeke Miller for the AP. Gensler “was an assistant Treasury secretary in the Clinton administration and later headed the CFTC during Barack Obama’s term. With a background of having worked for nearly 20 years at Wall Street powerhouse Goldman Sachs, Gensler surprised many by being a tough regulator of big banks as CFTC chairman.”

Bloomberg reporters Benjamin Bain, Jennifer Epstein and Robert Schmidt spotlight the work Prof. Gary Gensler, who has been nominated as the next chair of the Securities and Exchange Commission. Gensler “not only knows how to mobilize a bureaucratic federal agency but also understands the often impenetrable ways that Wall Street makes money -- and how firms use that complexity to turn regulation in their favor.”

Writing for The New Yorker, Sheelah Kolhatkar spotlights Biobot Analytics, an MIT startup that is studying sewage for the purpose of tracking diseases and the spread of Covid-19. “It’s about our health and well-being in general,” says Biobot co-founder and president Newsha Ghaeli. “It’s about understanding nutrition disparities in communities, understanding stress levels, pervasive infectious diseases like influenza or Zika virus.”

Prof. Gary Gensler will be the Biden administration’s pick to lead the Securities and Exchange Commission, reports Matthew Goldstein, Lauren Hirsch and Andrew Ross Sorkin for The New York Times. “Mr. Gensler is a veteran regulator who played a central role in bringing the big banks to heel in the aftermath of the 2008 financial crisis, giving new teeth to a watchdog agency.”

Prof. Eric Lander, president and founding director of the Broad Institute, and Maria Zuber, MIT’s vice president for research, have been nominated to leading roles on the Biden administration's science team, report Nidhi Subbaraman and Alexandra Witze for Nature. “These are excellent appointments, highly qualified and experienced, and well grounded in science,” says Rita Colwell, a professor at University of Maryland at College Park and former director of the National Science Foundation

CBS News spotlights how two MIT researchers have been named to key roles on the Biden administration’s science team. Prof. Eric Lander, president and founding director of the Broad Institute, has been nominated to lead the Office of Science and Technology Policy, and Maria Zuber, MIT’s vice president for research, will co-chair the President's Council of Advisors on Science and Technology. Zuber said she hopes to "restore trust in science, and pursue breakthroughs that benefit all people."

The Economist spotlights research by Professors Daron Acemoglu and David Autor examining how companies are adopting AI technologies, and the impact on the workforce and productivity. The researchers found, “machines are not yet depressing labour demand across the economy as a whole. As machines become cleverer, however, that could change.” 

AP reporter Seth Borenstein writes about how President-elect Joe Biden is nominating Prof. Eric Lander of the Broad Institute to serve as his chief science officer and lead the Office of Science and Technology Policy, and has selected Maria Zuber, vice president for research at MIT, to co-chair the President’s Council of Advisors on Science and Technology. Francis Collins, director of the NIH, called Lander, “brilliant, visionary, exceptionally creative and highly effective in aspiring others. I predict he will have a profound transformational effect on American science.”

Prof. Eric Lander, president and founding director of the Broad Institute, has been nominated by President-elect Joe Biden to lead the Office of Science and Technology Policy, which Biden will make a Cabinet-level position, reports Sarah Kaplan for The Washington Post. Maria Zuber, MIT’s vice president for research, will co-chair the President’s Council of Advisors on Science and Technology.

New York Times reporter Carl Zimmer writes that Prof. Eric Lander, president and founding director of the Broad Institute, has been nominated to serve as director of the Office of Science and Technology Policy and to serve as a presidential science advisor. MIT Vice President for Research Maria Zuber will co-chair the President’s Council of Advisors on Science and Technology.

A new study co-authored by MIT researchers finds that claims about superweapons are not realistic, reports William J. Broad for The New York Times. “There’re lots of claims and not many numbers,” says research affiliate David Wright. “If you put in the numbers, you find that the claims are nonsense.” 

MIT researchers have developed an online interactive tool aimed at helping consumers quantify the costs of buying an electric or gas-powered vehicle. The tool demonstrates how electric vehicles may initially be more expensive, but are often cheaper in the long-run, reports Veronica Penny for The New York Times. Prof. Jessika Trancik notes that she hopes the tool will “help people learn about how those upfront costs are spread over the lifetime of the car.”

Forbes contributor Adi Gaskell spotlights how the MIT Task Force on the Work of the Future recently released a comprehensive report examining the future of work. Gaskell writes that the Task Force's report emphasizes the “pressing issues of our time as one of improving the quality of jobs to ensure that prosperity is shared across the economy.”

Writing for Fast Company, Prof. Ramesh Raskar explores how to help improve distribution of the Covid-19 vaccine. Raskar and his co-author write that, “We must apply modern techniques like data analytics, user research, and usability testing to learn about the vaccine and immunization process from the perspective of different Americans, all while preserving privacy and people’s right to remain anonymous.” 

Boston Globe reporter Jon Chesto writes that MIT, Harvard, several research hospitals and life-sciences companies have selected a site for a new biologics manufacturing and innovation center. The project is aimed at expediting “discoveries for biotech treatments in university labs by allowing researchers to bypass the long waits that are common at contract manufacturers,” writesChesto.